This is driven by the increasing popularity of UCD.
According to Technavio, the global urea cycle disorder (UCD) treatment market is expected to grow by $215.4 million from 2024 to 2028, at a CAGR of 3.2%.
Rising investment in health care in developing countries is a key factor in this growth.
The increasing number of hospitals and healthcare spending in India and China has created huge opportunities for UCD treatment providers, the report said.
Additionally, as metabolic disorders increase, the need for advanced screening and management of UCD increases.
Although the market is growing, challenges remain due to limited access to specialized care, particularly in remote areas. The complexity of UCD treatment involves dietary changes, medications, and ammonia monitoring, resulting in delayed diagnosis and inadequate treatment.
It added that the pandemic had disrupted drug research and supply chains, but demand for Dublin treatments, particularly oral and injectable options, remained strong.
Meanwhile, the market is expected to continue to expand as healthcare systems adapt and innovate in UCD care.
